Johnson & Johnson (JNJ) has been amid a mix of outcomes, starting with facing its first U.K. lawsuits over alleged cancer-causing talcum powder, which led to a court order for the company to pay $966M in damages. On the business strategy side, the corporation has decided to avoid big acquisitions and emphasized its commitment to smaller deals while planning major changes. As such, JNJ decided to spin off its orthopedics unit, a move expected to speed up growth. Further, the company has reportedly been in negotiations to acquire Protagonist Therapeutics, enhancing its portfolio. Despite an earnings beat, JNJ shares have experienced a downturn, partly due to the talc verdict fallout. Jim Cramer has expressed his confidence in the stock’s ability to challenge Eli Lilly. However, share ownership has seen mixed movements, with numerous investment firms and wealth management companies either increasing or curtailing their stakes. In Q3 2025, JNJ exceeded earnings estimates attributed to strong growth in innovative sectors. The company seeks to make a significant impact on the treatment of plaque psoriasis following a U.S. FDA approval request for icotrokinra. Finally, JNJ’s Q3 earnings report brought a pleasant surprise as icotrokinra shined again, with the company revising its 2025 revenue outlook upwards.
Johnson Johnson JNJ News Analytics from Mon, 31 Mar 2025 07:00:00 GMT to Sat, 18 Oct 2025 16:07:05 GMT - Rating 4 - Innovation 7 - Information 9 - Rumor -6
